Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer August 5, 2025
JSKN003 Received FDA IND Approval to Initiate Ph 2 Study for Platinum-Resistant Ovarian Cancer August 5, 2025
First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer July 29, 2025
NDA submitted for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer July 15, 2025
Primary Results from Ph 2 RAMP 201 Trial of Avutometinib + Defactinib combo in Patients with Recurrent Low-Grade Serous Ovarian Cancer published in JCO July 15, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
Second patient dosed in Ph 2 trial protocol of stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer July 1, 2025
Results from Ph 1 FRAME Study of Avutometinib + Defactinib combo in Solid Tumors, including Low-Grade Serious Ovarian Cancer, published in Nature Medicine July 1, 2025
Ph 3 KEYNOTE-B96 Trial Met PFS Primary Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Patients Whose Tumors Expressed PD-L1 and in All Comers June 17, 2025
First Patient Enrolled in New Ph 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer June 3, 2025
Ph 3 KEYNOTE-B96 Trial Met Primary PFS Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers May 21, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer May 6, 2025
Clinical development of nemvaleukin to discontinue following review of data from Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials April 22, 2025
SON-1010 + Atezolizumab combo Demonstrates a Strong Safety Profile in Platinum-Resistant Ovarian Cancer patients April 15, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
Ph 3 Study Design Finalized with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer April 2, 2025
